Pharmabiz32m
KIMS inks MoU with Intuitive to launch 25 new robotic surgery programmes; Expanding accessibility in tier 2 & 3 cities
KIMS inks MoU with Intuitive to launch 25 new robotic surgery programmes; Expanding accessibility in tier 2 & 3 cities ...
Pharmabiz1h
Sapience Therapeutics begins patient enrolment in phase 2 study of first-in-class ß-catenin antagonist, ST316 in colorectal cancer
Tarrytown, New York Thursday, October 3, 2024, 15:00 Hrs [IST] ...
Pharmabiz1h
CDSCO becomes affiliated member of IMDRF
The Central Drugs Standard Control Organization (CDSCO) has received approval from International Medical Device Regulators Forum (IMDRF) as an affiliate member of the Forum. The ministry of health and ...
Pharmabiz2h
Qiagen introduces QIAcuityDx digital PCR system for clinical testing in oncology
Qiagen introduces QIAcuityDx digital PCR system for clinical testing in oncology: Venlo, the Netherlands Thursday, October 3, 2024, 14:00 Hrs [IST] Qiagen N.V., a Netherlands-base ...
Pharmabiz4h
Biocon Biologics refinances US$ 1.1 billion long term debt through US$ bonds and new syndicated facility
Biocon Biologics refinances US$ 1.1 billion long term debt through US$ bonds and new syndicated facility: Our Bureau, Bengaluru Thursday, October 3, 2024, 12:30 Hrs [IST] Biocon B ...
Pharmabiz4h
UNAIDS welcomes Gilead’s voluntary licensing agreements on HIV drug lenacapavir
UNAIDS welcomes Gilead’s voluntary licensing agreements on HIV drug lenacapavir: Our Bureau, New Delhi Thursday, October 3, 2024, 12:10 Hrs [IST] The Joint United Nations Progra ...
Pharmabiz4h
Moderna doses first participant in phase 3 trial of mRNA norovirus vaccine, mRNA-1403
Moderna doses first participant in phase 3 trial of mRNA norovirus vaccine, mRNA-1403: Cambridge, Massachusetts Thursday, October 3, 2024, 12:00 Hrs [IST] Moderna, Inc, a global l ...
Pharmabiz4h
Gilead's licensing agreement for lenacapavir a move to preserve its monopoly, alleges TWN
Gilead's licensing agreement for lenacapavir a move to preserve its monopoly, alleges TWN: Our Bureau, New Delhi Thursday, October 3, 2024, 12:20 Hrs [IST] Third World Network (TW ...
Pharmabiz4h
FIP publishes reference document on access to safe and quality essential medicines
FIP publishes reference document on access to safe and quality essential medicines: Our Bureau, Bengaluru Thursday, October 3, 2024, 12:45 Hrs [IST] International Pharmaceutical F ...
Pharmabiz5h
Gilead Sciences signs voluntary licensing agreement with six pharma firms to produce generic lenacapavir
Gilead Sciences signs voluntary licensing agreement with six pharma firms to produce generic lenacapavir: Our Bureau, New Delhi Thursday, October 3, 2024, 11:30 Hrs [IST] US-based ...
Pharmabiz5h
Eppendorf introduces CO2 incubator shaker, CellXpert CS220 on the market with integrated 180°C sterilization routine
Eppendorf introduces CO2 incubator shaker, CellXpert CS220 on the market with integrated 180°C sterilization routine: Hamburg, Germany Thursday, October 3, 2024, 11:00 Hrs [IST] ...
Pharmabiz6h
Merck completes acquisition of investigational B-cell depletion therapy, CN201 from Curon Biopharma
Merck completes acquisition of investigational B-cell depletion therapy, CN201 from Curon Biopharma: Rahway, New Jersey Thursday, October 3, 2024, 10:00 Hrs [IST] Merck, known as ...